A phase II proof-of-concept trial of XEN1101

Trial Profile

A phase II proof-of-concept trial of XEN1101

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs XEN 1101 (Primary)
  • Indications Partial epilepsies
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2017 New trial record
    • 07 Nov 2017 According to a Xenon Pharmaceuticals media release, this study is anticipated to begin in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top